Integrated genomic characterization of endometrial carcinoma
Open accessAbstract
SummaryWe performed an integrated genomic, transcriptomic, and proteomic characterization of 373 endometrial carcinomas using array- and sequencing-based technologies. Uterine serous tumors and ~25% of high-grade endometrioid tumors have extensive copy number alterations, few DNA methylation changes, low ER/PR levels, and frequent TP53 mutations. Most endometrioid tumors have few copy number alterations or TP53 mutations but frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A, KRAS and novel mutations in the SWI/SNF gene ARID5B. A subset of endometrioid tumors we identified had a dramatically increased transversion mutation frequency, and newly identified hotspot mutations in POLE. Our results classified endometrial cancers into four categories: POLE ultramutated, microsatellite instability hypermutated, copy number low, and copy number high. Uterine serous carcinomas share genomic features with ovarian serous and basal-like breast carcinomas. We demonstrated that the genomic features of endometrial carcinomas permit a reclassification that may impact post-surgical adjuvant treatment for women with aggressive tumors.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Androgen receptor is upregulated in 9.8% of grade 3 endometrial adenocarcinoma samples.
“AR is up-regulated in 9.8% of endometrial adenocarcinoma grade 3 samples [63, 90].”
From Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism (2014) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dubrawsky, N. (1989) · Ca · doi:10.3322/canjclin.39.6.399 · Cited by 84,410
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129 · see citing works
Self-citationSiegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825 · see citing works
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · see citing works
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720 · see citing works
Mermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. M., Beroukhim, R., & Getz, G. A. (2011) · Genome biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,469 · see citing works
Self-citationCpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,525 · see citing works
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337 · see citing works
Self-citationMetagenes and molecular pattern discovery using matrix factorization
Brunet, J.-P., Tamayo, P., Golub, T. R., & Mesirov, J. P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308531101 · Cited by 2,183 · see citing works
A comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696 · see citing works
A flexible R package for nonnegative matrix factorization
Gaujoux, R., & Seoighe, C. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-367 · Cited by 1,554 · see citing works
Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., Kanchi, K., Maher, C. A., Fulton, R. S., Fulton, L., Wallis, J. W., et al. (2012) · Cell · doi:10.1016/j.cell.2012.08.024 · Cited by 1,144 · see citing works
Self-citationPalles, C., Cazier, J., Howarth, K. M., Domingo, E., Jones, A. M., Broderick, P., Kemp, Z., Spain, S. L., Guarino, E., Salguero, I., et al. (2012) · Nature Genetics · doi:10.1038/ng.2503 · Cited by 995 · see citing works
Shen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849 · see citing works
Vaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786 · see citing works
Mutual exclusivity analysis identifies oncogenic network modulesPreprint
Ciriello, G., Cerami, E. G., Sander, C., & Schultz, N. D. (2011) · Genome Research · doi:10.1101/gr.125567.111 · Cited by 676 · see citing works
Genome-scale analysis of aberrant DNA methylation in colorectal cancerPreprint
Hinoue, T., Weisenberger, D. J., Lange, C., Shen, H., Byun, H., Van, D., Malik, S., Pan, F., Noushmehr, H., van, C., et al. (2011) · Genome Research · doi:10.1101/gr.117523.110 · Cited by 604 · see citing works
Fleming, G. F., Brunetto, V. L., Cella, D. F., Look, K. Y., Reid, G. C., Munkarah, A. R., KLINE, R. C., Burger, R. A., Goodman, A., & Burks, R. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.184 · Cited by 565 · see citing works
Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke‐Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 471 · see citing works
Gallo, M. L., O’Hara, A. J., Rudd, M. L., Urick, M. E., Hansen, N. F., O’Neil, N. J., Price, J. C., Zhang, S., England, B. M., Godwin, A. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2455 · Cited by 418 · see citing works
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
Gilks, C. B., Oliva, E., & Soslow, R. A. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f576a · Cited by 404 · see citing works
Pollock, P., Gartside, M., Dejeza, L., Powell, M., Mallon, M. A., Davies, H., Mohammadi, M., Futreal, P., Stratton, M. R., Trent, J., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210529 · Cited by 346 · see citing works
Regulation of Wnt Signaling by Sox Proteins
Zorn, A. M., Barish, G. D., Williams, B. O., Lavender, P., Klymkowsky, M. W., & VARMUS, H. E. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80200-2 · Cited by 342 · see citing works
Sinner, D. I., Kordich, J. J., Spence, J. R., Opoka, R. J., Rankin, S. A., Lin, S. J., Jonatan, D., Zorn, A. M., & Wells, J. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02179-06 · Cited by 321 · see citing works
Use of mutation profiles to refine the classification of endometrial carcinomas
McConechy, M. K., Ding, J., Cheang, M. C. U., Wiegand, K. C., Senz, J., Tone, A. A., Yang, W., Prentice, L., Tse, K., Zeng, T., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4056 · Cited by 301 · see citing works
Fleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P., Horowitz, I., et al. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300 · see citing works
Salvesen, H., Carter, S., Mannelqvist, M., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0806514106 · Cited by 289 · cited 1× · see citing works
“Tumour samples and corresponding germline DNA were collected from 373 patients, including 307 endometrioid and 66 serous (53) or mixed histology (13) cases.”
BackgroundSelf-citationIdentification of Molecular Pathway Aberrations in Uterine Serous Carcinoma by Genome-wide Analyses
Kuhn, E., Wu, R., Guan, B., Wu, G., Zhang, J., Wang, Y., Song, L., Yuan, X., Wei, L., Roden, R. B. S., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs345 · Cited by 249 · see citing works
PIK3R1 (p85α) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
Urick, M. E., Rudd, M. L., Godwin, A. K., Sgroi, D. C., Merino, M. J., & Bell, D. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0549 · Cited by 230 · see citing works
Houseman, E. A., Christensen, B. C., Yeh, R., Marsit, C. J., Karagas, M. R., Wrensch, M., Nelson, H. H., Wiemels, J. L., Zheng, S., Wiencke, J. K., et al. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-365 · Cited by 208 · see citing works
Zighelboim, I., Goodfellow, P. J., Gao, F., Gibb, R. K., Powell, M. A., Rader, J. S., & Mutch, D. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2107 · Cited by 202 · see citing works
Byron, S. A., Gartside, M. G., Powell, M. A., Wellens, C. L., Gao, F., Mutch, D. G., Goodfellow, P. J., & Pollock, P. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030801 · Cited by 187 · see citing works
Yemelyanova, A. V., Ji, H., Shih, I., Wang, T., Wu, L.-S.-F., & Ronnett, B. M. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181ac35f5 · Cited by 182 · see citing works
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129 · see citing works
Self-citationCowin, P. A., George, J., Fereday, S., Loehrer, E. A., Loo, P. V., Cullinane, C. M., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0203 · Cited by 109 · see citing works
Oncogenic K-ras Stimulates Wnt Signaling in Colon Cancer Through Inhibition of GSK-3β
Li, J., Mizukami, Y., Zhang, X., Jo, W., & Chung, D. C. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.02.067 · Cited by 107 · see citing works
Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type
Clarke, B., & Gilks, C. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.071225 · Cited by 106
Sutton, G., Axelrod, J., Bundy, B., et al. (2005) · Gynecologic Oncology · doi:10.1097/01.ogx.0000180852.52886.da · Cited by 105
Bartosch, C., Lopes, J. M., & Oliva, E. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318234ab18 · Cited by 101 · see citing works
Palles, C., Cazier, J., Howarth, K., et al. (2013) · Nature Genetics · doi:10.1038/ng0613-713b · Cited by 59
Flagged first, then by citations
Research works printed but not linked: 1
- Martin L. Ferguson 69 , John A. Demchok 67 , Liming Yang 67 ; National Human Genome Research Institute Mark S. Guyer 70 , Bradley A. Ozenberger 70 , Heidi J. Sofia 70 Writing committee: Cyriac Kandoth 2 , Nikolaus Schultz 24 , Andrew D. Cherniack 1 , Rehan Akbani 33 , Yuexin Liu 30,31 , Hui Shen 22 , A. Gordon Robertson 3 , Itai Pashtan 1,4,5 , Ronglai Shen 27 , Christopher C. Benz 29 , Christina Yau 29 , Peter W. Laird 22 , Li Ding 2 , Wei Zhang 30,31 , Gordon B. Mills 34 , Raju Kucherlapati 9 , Elaine R. Mardis 2 & Douglas A. Levine 51 1 The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University Cambridge, Massachusetts 02142, USA.
Cited by
Sorted by citations
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · see citing works
Self-citationSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · see citing works
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498 · see citing works
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419 · see citing works
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725 · see citing works
“Thus, the event time for OS and PFI derived from this TCGA dataset is consistent with the literature, an observation previously noted for OS in the initial GBM marker paper when only 185 cases were analyzed (Cancer Genome Atlas Research Network, 2008).”
ResultSelf-citationOncogenic Signaling Pathways in The Cancer Genome Atlas
Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W. K., Luna, A., La, K. C., Dimitriadoy, S., Liu, D. L., Kantheti, H. S., Saghafinia, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.035 · Cited by 3,201 · see citing works
Self-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096 · see citing works
Hoadley, K. A., Yau, C., Hinoue, T., Wolf, D. M., Lazar, A. J., Drill, E., Shen, R., Taylor, A. M., Cherniack, A. D., Thorsson, V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.022 · Cited by 2,546 · see citing works
Self-citationThe landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572 · see citing works
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462 · see citing works
Kather, J. N., Pearson, A. T., Halama, N., Jäger, D., Krause, J., Loosen, S. H., Marx, A., Boor, P., Tacke, F., Neumann, U. P., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0462-y · Cited by 1,458 · see citing works
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257 · see citing works
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145 · see citing works
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · see citing works
The whole-genome landscape of medulloblastoma subtypes
Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., et al. (2017) · Nature · doi:10.1038/nature22973 · Cited by 1,112 · see citing works
Davoli, T., Xu, A. W., Mengwasser, K. E., Sack, L. M., Yoon, J. C., Park, P. J., & Elledge, S. J. (2013) · Cell · doi:10.1016/j.cell.2013.10.011 · Cited by 815 · see citing works
Liu, J., Eckert, M. A., Harada, B. T., Liu, S., Lu, Z., Yu, K., Tienda, S. M., Chryplewicz, A., Zhu, A. C., Yang, Y., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0174-4 · Cited by 781 · see citing works
“Sequencing studies have found that the METTL14 subunit of the core m 6 A methyltransferase complex is frequently mutated in endometrial tumors 36 , but the relevance of these mutations and of m 6 A mRNA methylation to the disease has not yet been established.”
InfluentialChang, M. T., Asthana, S., Gao, S. P., Lee, B. H., Chapman, J. S., Kandoth, C., Gao, J., Socci, N. D., Solit, D. B., Olshen, A. B., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3391 · Cited by 808 · see citing works
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S. J., Stover, E. H., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 687 · see citing works
Systems genetics approaches to understand complex traits
Civelek, M., & Lusis, A. J. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3575 · Cited by 621 · see citing works
“For example, a recent study from The Cancer Genome Atlas project revealed similarities between some endometrial cancers and subtypes of ovarian and breast cancers 91 .”
ResultProteogenomic Characterization of Endometrial Carcinoma
Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485 · see citing works
Self-citationLenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522 · see citing works
“MSI-H tumors with high mutational burdens are more susceptible to checkpoint inhibitors,(11) and the mutational burden in MSI-H endometrial cancers is particularly high.(12) Pembrolizumab has demonstrated efficacy in patients with MSI-H endometrial cancer.”
BackgroundGenome-wide analysis of noncoding regulatory mutations in cancer
Weinhold, N., Jacobsen, A., Schultz, N., Sander, C., & Lee, W. (2014) · Nature Genetics · doi:10.1038/ng.3101 · Cited by 484 · see citing works
The mutational landscape of normal human endometrial epithelium
Moore, L., Leongamornlert, D., Coorens, T. H. H., Sanders, M. A., Ellis, P., Dentro, S. C., Dawson, K. J., Butler, T., Rahbari, R., Mitchell, T. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2214-z · Cited by 499 · see citing works
Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
Alexandrov, L. B., & Stratton, M. R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.014 · Cited by 488 · see citing works
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486 · see citing works
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology
Shmatko, A., Ghaffari Laleh, N., Gerstung, M., & Kather, J. N. (2022) · Nature Cancer · doi:10.1038/s43018-022-00436-4 · Cited by 446 · see citing works
Goode, E. L., Block, M. S., Kalli, K. R., Vierkant, R. A., Chen, W., Fogarty, Z. C., Gentry‐Maharaj, A., Toloczko, A. D., Hein, A., Bouligny, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3290 · Cited by 396 · see citing works
Clinical actionability of molecular targets in endometrial cancer
Urick, M. E., & Bell, D. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0177-x · Cited by 405 · see citing works
Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities
Davis, R. J., Welcker, M., & Clurman, B. E. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.013 · Cited by 343 · see citing works
Singh, N., Piskorz, A., Bosse, T., Jimenez‐Liñan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2019) · The Journal of Pathology · doi:10.1002/path.5375 · Cited by 319 · see citing works
“In the molecular classification of EC, the presence of TP53 mutation or p53abn IHC is only a surrogate for CN-high molecular subtype if the POLEmut and MMRd tumours are excluded [7,14,17].”
BackgroundInfluentialPromoter-proximal CTCF binding promotes distal enhancer-dependent gene activation
Kubo, N., Ishii, H., Xiong, X., Bianco, S., Meitinger, F., Hu, R., Hocker, J. D., Conte, M., Gorkin, D., Yu, M., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-00539-5 · Cited by 289 · see citing works
Domingo, E., Freeman-Mills, L., Rayner, E., Glaire, M., Briggs, S., Vermeulen, L., Fessler, E., Medema, J. P., Boot, A., Morreau, H., et al. (2016) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(16)30014-0 · Cited by 308 · see citing works
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data
Mo, Q., Shen, R., Guo, C., Vannucci, M., Chan, K. S., & Hilsenbeck, S. G. (2017) · Biostatistics · doi:10.1093/biostatistics/kxx017 · Cited by 281 · see citing works
Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 285 · see citing works
Integrative multi-omics approaches in cancer research: from biological networks to clinical subtypes
Heo, Y. J., Hwa, C., Lee, G.-H., Park, J.-M., & An, J.-Y. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0042 · Cited by 294 · see citing works
AKT in cancer: new molecular insights and advances in drug development
Mundi, P. S., Sachdev, J., McCourt, C., & Kalinsky, K. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13021 · Cited by 272 · see citing works
Structural Basis for the Versatile and Methylation-Dependent Binding of CTCF to DNA
Hashimoto, H., Wang, D., Horton, J. R., Zhang, X., Corces, V. G., & Cheng, X. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.05.004 · Cited by 268 · see citing works
Shu, C. A., Pike, M. C., Jotwani, A. R., Friebel, T. M., Soslow, R. A., Levine, D. A., Nathanson, K. L., Konner, J. A., Arnold, A. G., Bogomolniy, F., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1820 · Cited by 232 · see citing works
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism
Rižner, T. L., & Penning, T. M. (2014) · Steroids · doi:10.1016/j.steroids.2013.10.012 · Cited by 217 · see citing works
Macroscopic somatic clonal expansion in morphologically normal human urothelium
Li, R., Du, Y., Chen, Z., Xu, D., Lin, T., Jin, S., Wang, G., Liu, Z., Lu, M., Chen, X., et al. (2020) · Science · doi:10.1126/science.aba7300 · Cited by 206 · see citing works
Characterizing DNA methylation alterations from The Cancer Genome Atlas
Weisenberger, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69740 · Cited by 200 · see citing works
Vermij, L., Jobsen, J. J., León‐Castillo, A., Brinkhuis, M., Roothaan, S. M., Powell, M. E. B., de Boer, S. M., Khaw, P., Mileshkin, L., Fyles, A., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02141-0 · Cited by 193 · see citing works
“In the TCGA analyses, pathogenic TP53mutations were present in 90% of copy number-high tumours [40].”
BackgroundMcCluggage, W. G., Singh, N., & Gilks, C. B. (2022) · Histopathology · doi:10.1111/his.14609 · Cited by 199 · see citing works
“In contrast to tubo-ovarian HGSC, however, some p53abn endometrial carcinomas have recurrent mutations in PIK3CA, FBXW7, and PPP2R1A46; they are less likely to have mutations in BRCA1 or BRCA2 than is tubo-ovarian HGSC.46,67 HER2 amplification occurs in ~20% of this molecular subtype, and a proportion have homologous…”
BackgroundInfluentialIncreased somatic mutation burdens in normal human cells due to defective DNA polymerases
Robinson, P. S., Coorens, T. H. H., Palles, C., Mitchell, E., Abascal, F., Olafsson, S., Lee, B. C. H., Lawson, A. R. J., Lee-Six, H., Moore, L., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00930-y · Cited by 173 · see citing works
Choucair, K., Morand, S. M., Stanbery, L., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0174-y · Cited by 165 · see citing works
Protein neddylation and its role in health and diseases
Zhang, S., Yu, Q., Li, Z., Zhao, Y., & Sun, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01800-9 · Cited by 171 · see citing works
McAlpine, J. N., Chiu, D. S., Nout, R. A., Church, D. N., Schmidt, P., Lam, S., Leung, S. C. Y., Bellone, S., Wong, A., Brucker, S. Y., et al. (2021) · Cancer · doi:10.1002/cncr.33516 · Cited by 170 · see citing works
“8 The Cancer Genome Atlas (TCGA)(9) identified a novel subgroup of ECs with mutations in DNA polymerase epsilon (POLE) that are responsible for DNA replication and lead to exceedingly high somatic mutation frequencies (“ultramutated”: >100 mutations per megabase).(9) It is now recognized that approximately 5% to 10% o…”
BackgroundEfficient Use of Patient-Derived Organoids as a Preclinical Model for Gynecologic Tumors
Maru, Y., Tanaka, N., Itami, M., & Hippo, Y. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.05.005 · Cited by 162 · see citing works
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16318 · Cited by 163 · see citing works
“73 For women with cervical cancer, surgery is reserved for those without evidence of bulky cervical disease (primary cervical lesion 4 cm or larger) or other advanced features (eg, local invasion beyond the uterus).”
BackgroundSelf-citationSantin, A. D., Bellone, S., Buza, N., Choi, J., Schwartz, P. E., Schlessinger, J., & Lifton, R. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1031 · Cited by 161 · see citing works
“POLE ultra-mutated tumors account for 7% to 12% of all endometrial carcinomas (1, 2, 5, 6) and occur secondary to mutations in the exonuclease domain of POLE, a nuclear DNA polymerase endowed with intrinsic proofreading activity (5).”
BackgroundInfluentialJiao, Y., Widschwendter, M., & Teschendorff, A. E. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu316 · Cited by 148 · see citing works
“Thus, in order to validate our method of summarizing Illumina 450k DNAm data at the gene-level, we decided to apply the EpiMod and FEM algorithms to an independent endometrial normal/cancer Infinium 450k set generated as part of the TCGA (Methods) (Kandoth et al., 2013).”
BackgroundMethodInfluentialMurali, R., DeLair, D. F., Bean, S. M., Abu‐Rustum, N. R., & Soslow, R. A. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7066 · Cited by 137 · see citing works
Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz291 · Cited by 151 · see citing works
Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis
Huvila, J. K., Pors, J., Thompson, E. F., & Gilks, C. B. (2020) · The Journal of Pathology · doi:10.1002/path.5608 · Cited by 149 · see citing works
“In 2013, The Cancer Genome Atlas (TCGA) identified four molecular subtypes of EC based on genomic features [10].”
BackgroundOncogenic mutations in histologically normal endometrium: the new normal?
Lac, V., Nazeran, T. M., Tessier‐Cloutier, B., Aguirre-Hernández, R., Albert, A., Lum, A. M., Khattra, J. S., Praetorius, T., Mason, M., Chiu, D. S., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5314 · Cited by 139 · see citing works
“Comparing our data to the TCGA endometrial cancer dataset reveals that the prevalence of driver mutations is higher across age in endometrial cancer (or comparably as uncommon) in all genes except for KRAS.”
BackgroundResultInfluentialRole of POLE and POLD1 in familial cancer
Mur, P., García‐Mulero, S., Valle, J. D., Magraner-Pardo, L., Vidal, A., Pineda, M., Cinnirella, G., Martin, E. J., Pons, T., López‐Doriga, A., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0922-2 · Cited by 140 · see citing works
Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome
Hollis, R. L., Thomson, J. P., Stanley, B., Churchman, M., Meynert, A. M., Rye, T., Bartos, C., Iida, Y., Croy, I., Mackean, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18819-5 · Cited by 141 · see citing works
Ring, K. L., Mills, A. M., & Modesitt, S. C. (2022) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004989 · Cited by 138 · see citing works
Collateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132 · see citing works
Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells
Perry, J. M., Fang, T., Roy, A., Lin, T. L., He, X., Chen, S., Lü, X., Nemechek, J. M., Ruan, L., Yu, X., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0507-y · Cited by 137 · see citing works
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143 · see citing works
Haesen, D., Abbasi Asbagh, L., Derua, R., Hubert, A., Schrauwen, S., Hoorne, Y., Amant, F., Waelkens, E., Sablina, A., & Janssens, V. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3342 · Cited by 124 · see citing works
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129 · see citing works
Pasanen, A. M., Loukovaara, M. J., & Bützow, R. C. (2020) · Modern Pathology · doi:10.1038/s41379-020-0501-8 · Cited by 129 · see citing works
“MMRd carcinomas rarely displayed aberrant p53 or L1CAM positivity, both considered molecular markers of aggressive EC [1, 27, 46, 47].”
BackgroundMethodInfluentialUnderstanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110 · see citing works
Solid Tumors Challenges and New Insights of CAR T Cell Engineering
Tahmasebi, S., Elahi, R., & Esmaeilzadeh, A. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09901-7 · Cited by 111 · see citing works
Kolin, D. L., Quick, C. M., Dong, F., Fletcher, C. D. �., Stewart, C. J. R., Soma, A., Hornick, J. L., Nucci, M. R., & Howitt, B. E. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001375 · Cited by 111 · see citing works
Moving pan-cancer studies from basic research toward the clinic
Chen, F., Wendl, M. C., Wyczalkowski, M. A., Bailey, M. H., Li, Y., & Ding, L. (2021) · Nature Cancer · doi:10.1038/s43018-021-00250-4 · Cited by 107 · see citing works
Self-citationZaffaroni, G., Mannucci, A., Koskenvuo, L. E., de Lacy, F. B., Maffioli, A., Bisseling, T. M., Half, E., Cavestro, G. M., Valle, L., Ryan, N. A. J., et al. (2024) · British journal of surgery · doi:10.1093/bjs/znae070 · Cited by 111 · see citing works
Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons.
Bakkum-Gamez, J. N., Wentzensen, N., Maurer, M. J., Hawthorne, K. M., Voss, J. S., Kroneman, T. N., Famuyide, A. O., Clayton, A. C., Halling, K. C., Kerr, S. E., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.01.552 · Cited by 107 · see citing works
Raynaud, F., Mina, M., Tavernari, D., & Ciriello, G. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007669 · Cited by 101 · see citing works
New perspectives on screening and early detection of endometrial cancer
Costas, L., Frias‐Gomez, J., Guardiola, M., Benavente, Y., Pineda, M., Pavón, M. Á., Martínez, J. M., Climent, M., Barahona, M., Canet, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32514 · Cited by 100 · see citing works
“Although the dualistic classification system remains the gold standard, a new classification system by The Cancer Genome Atlas (TCGA) Consortium based on molecular features is starting to be integrated into clinical practice.(9,10) In contrast to many common diseases that could be detected preclinically, but screening…”
BackgroundCochrane, D. R., Campbell, K. R., Greening, K., Ho, G. C., Hopkins, J., Bui, M., Douglas, J. M., Sharlandjieva, V., Munzur, A. D., Lai, D., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5511 · Cited by 84 · see citing works
“The Cancer Genome Atlas (TCGA) demonstrated that endometrial carcinoma patients could be differentiated into four prognostically distinct subgroups [22].”
BackgroundNetwork Medicine in Pathobiology
Lee, L. Y.-H., & Loscalzo, J. (2019) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.03.009 · Cited by 95 · see citing works
“Oncologic research is one of the leading areas in which PARADIGM or similar algorithms have been widely adopted to integrate multiplatform patient data.(90) One of these multi-omic cancer studies recently added a novel dimension of antitumor immunity profiles to guide personalized immunotherapy.”
BackgroundAlterations of DNA damage repair in cancer: from mechanisms to applications
Jiang, M., Jia, K., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., He, Y., & Zhou, C. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2920 · Cited by 84 · see citing works
“Kandoth et al. identified the frequencies of MSI in DNA polymerase epsilon ( POLE ) mutations in endometrial and colorectal cancers to be 40% and 11%, respectively, and the mutation rates to be 7% and 3%, respectively (26).”
Rahmanto, Y. S., Shen, W., Shi, X., Chen, X. X., Yu, Y., Yu, Z.-C., Miyamoto, T., Lee, M.-H., Singh, V., Asaka, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16416-0 · Cited by 93 · see citing works
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer
Horeweg, N., de Bruyn, M., Nout, R. A., Stelloo, E., Kedzierska, K., León‐Castillo, A., Plat, A., Mertz, K. D., Osse, M., Jurgenliemk-Schulz, I. M., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0149 · Cited by 82 · see citing works
Cancer-associated mutations in endometriosis: shedding light on the pathogenesis and pathophysiology
Guo, S.-W. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz047 · Cited by 96 · see citing works
Nesic, K., Kondrashova, O., Hurley, R. M., McGehee, C. D., Vandenberg, C. J., Ho, G., Lieschke, E., Dall, G., Bound, N. T., Shield‐Artin, K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0774 · Cited by 90 · see citing works
Costigan, D. C., Dong, F., Nucci, M. R., & Howitt, B. E. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000583 · Cited by 90 · see citing works
“Given that previous studies have shown that the association of CTNNB1 mutated tumors with poor prognosis was dependent on molecular subgroup (9), we examined our stage IA exon 3 mutated tumors in the context of other significant molecular classifiers in TCGA classification system (6); almost 80% of tumors were TP53 an…”
MethodResultPhenotype of POLE-mutated endometrial cancer
Imboden, S., Nastic, D., Ghaderi, M., Rydberg, F., Rau, T. T., Mueller, M. D., Epstein, E., & Carlson, J. W. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214318 · Cited by 87 · see citing works
Past, present, and future of hormonal therapy in recurrent endometrial cancer
Leslie, K. K., Thiel, K. W., & Carlson, M. J. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s40942 · Cited by 84 · see citing works
Molecular subtypes of endometrial cancer: Implications for adjuvant treatment strategies
Yang, Y., Wu, S. F., & Bao, W. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14969 · Cited by 89 · see citing works
“15 The first group, hypermutated, had somatic inactivating mutations in the exonuclease domain of polymerase epsilon (POLE), resulting in a very high mutation rate and excellent prognosis (7%).”
BackgroundGenetic characteristics of gastric-type mucinous carcinoma of the uterine cervix
Park, E., Kim, S. W., Kim, S., Kim, H.-S., Lee, J., Kim, Y. T., & Cho, N. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0614-0 · Cited by 78 · see citing works
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Ambrosini, M., Manca, P., Nasca, V., Sciortino, C., Ghelardi, F., Seligmann, J. F., Taı̈eb, J., & Pietrantonio, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01015-z · Cited by 91 · see citing works
Evidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73 · see citing works
Dysregulated FGF signalling in neoplastic disorders
Tanner, Y., & Grose, R. P. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.012 · Cited by 75 · see citing works
Reverse phase protein arrays in signaling pathways: a data integration perspective
Huang, S., & Creighton, C. J. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s38375 · Cited by 68 · see citing works
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells
Pasanen, A. M., Ahvenainen, T., Pellinen, T. S., Vahteristo, P., Loukovaara, M. J., & Bützow, R. C. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001395 · Cited by 70 · see citing works
Krämer, P., Talhouk, A., Brett, M. A., Chiu, D. S., Cairns, E. S., Scheunhage, D. A., Hammond, R. F. L., Farnell, D., Nazeran, T. M., Grube, M. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1268 · Cited by 67 · see citing works
Casey, L., & Singh, N. (2020) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000710 · Cited by 68 · see citing works
“About 7% to 12% of ECs demonstrate mutations in the exonuclease domain of POLE (11,14).”
BackgroundMethodBrett, M. A., Atenafu, E. G., Singh, N., Ghatage, P., Clarke, B. A., Nelson, G. S., Bernardini, M. Q., & Köbel, M. (2020) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000674 · Cited by 65 · see citing works
“A molecular subtype classification has been proposed for endometrial carcinoma following The Cancer Genome Atlas (TCGA) project (1).”
BackgroundResultInfluentialBrain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64 · see citing works
Molecular characterization of endometrial cancer and therapeutic implications
Winterhoff, B. J. N., Thomaier, L., Mullany, S. A., & Powell, M. A. (2019) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000602 · Cited by 59 · see citing works
Clear cell endometrial carcinoma and the TCGA classification
Travaglino, A., Raffone, A., Mascolo, M., Guida, M., Insabato, L., Zannoni, G. F., & Zullo, F. (2019) · Histopathology · doi:10.1111/his.13976 · Cited by 65 · see citing works
“Conversely, the CNH subgroup (also referred to as the ‘serous’ subgroup) is mainly composed of serous carcinomas and bears the worst prognosis among all TCGA subgroups.(1) Therefore, it might be hypothesized that some CCCs are biologically similar to endometrioid carcinoma and have a better prognosis, while some are s…”
BackgroundInfluentialYasin, H. K., Taylor, A. H., & Ayakannu, T. (2021) · Cancers · doi:10.3390/cancers13092149 · Cited by 63 · see citing works
“Copy number groups are defined by a differential profile of copy alterations (CNA), with the CNH group particularly presenting an elevated incidence of tumour suppressor p53 (TP53) mutations and worse prognosis when compared to the low copy number group [70].”
BackgroundMethodTime Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer
Matsuo, K., Opper, N. R., Ciccone, M. A., et al. (2015) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000636 · Cited by 62 · see citing works
- Authors
- The Cancer Genome Atlas Research Network, & Levine, D. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Levine, Douglas A.
- ORCID
- Levine, Douglas A.
- Venue
- Nature
- Published
- 2013-05-01
- Volume
- 497
- Issue
- 7447
- Pages
- 67-73
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3704730
- OpenAlex
- W2041440766
- Cited by
- 5,784
- References
- 40
- Citations by year
- 2026: 467 · 2025: 580 · 2024: 559 · 2023: 595 · 2022: 591 · 2021: 572 · 2020: 455 · 2019: 384 · 2018: 320 · 2017: 328 · 2016: 313 · 2015: 285 · 2014: 231 · 2013: 96 · 2012: 5
- FWCI
- 345.78
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-06-12)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (P50CA098258, U24CA143882, R01CA180006, U24CA143843, U24CA143840, U24CA143858, U24CA144025, U24CA143866, U24CA143883, U24CA143845, U24CA143867, U24CA143848, U24CA143799, U24CA143835, P30CA008748, P30CA016672, P30CA016056, P30CA016086)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- endometrial cancer, uterine serous carcinoma, endometrioid carcinoma, copy number alterations, TP53 mutation, POLE mutation, microsatellite instability, ARID5B, SWI/SNF chromatin remodeling, CTNNB1, PIK3CA, KRAS, PTEN, DNA methylation, oestrogen receptor, progesterone receptor, adjuvant therapy, genomic profiling
- MeSH terms
- Poly-ADP-Ribose Binding Proteins, Breast Neoplasms, Chromosome Aberrations, DNA Mutational Analysis, DNA Polymerase II, DNA-Binding Proteins, Female, Humans, Ovarian Neoplasms, Transcription Factors, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Endometrial Neoplasms, Genomics, DNA Copy Number Variations, Exome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
